Metronomic chemotherapy from rationale to clinical studies

A dream or reality?

Antonio Gnoni, Nicola Silvestris, Antonella Licchetta, Daniele Santini, Mario Scartozzi, Roberto Ria, Salvatore Pisconti, Fausto Petrelli, Angelo Vacca, Vito Lorusso

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Metronomic chemotherapy (MC) refers to the close administration of a chemotherapeutic drug for a long time with no extended drug-free breaks. It was developed to overcome drug resistance, partly by shifting the therapeutic target from tumor cells to the tumor vasculature, with less toxicity. Because of this peculiar way of administration, MC can be viewed as a form of long-term 'maintenance' treatment, and can be integrated with standard and conventional chemotherapy in a "chemo-switching" strategy. Additional mechanisms are involved in its antitumor activity, such as activation of immunity, induction of tumor dormancy, chemotherapy-driven dependency of cancer cells, and the '4D effect'. In this paper we report the most important studies that have analyzed these processes. In fact, a number of preclinical and clinical studies in solid tumors as well as in multiple myeloma, have been reported regarding several chemotherapy drugs which have been proposed with a metronomic schedule: vinorelbine, cyclophosphamide, capecitabine, methotrexate, bevacizumab, etoposide, gemcitabine, sorafenib, everolimus and temozolomide. The results of these studies have been sometimes conflicting, highlighting the need to develop reliable tools for patient selection and stratification. However, a more precise evaluation of MC strategies with the ongoing randomized phase II/III clinical is fundamental, because of the strict correlation of this approach with translational research and target therapy. Moreover, because of the low toxicity of MC, these studies will also help to better evaluate the clinical benefit of this treatment, with a special focus on elderly and low performance status patients.

Original languageEnglish
Pages (from-to)46-61
Number of pages16
JournalCritical Reviews in Oncology/Hematology
Volume95
Issue number1
DOIs
Publication statusPublished - Jul 1 2015

Fingerprint

Drug Therapy
temozolomide
Neoplasms
gemcitabine
Metronomic Administration
Pharmaceutical Preparations
Translational Medical Research
Etoposide
Therapeutics
Clinical Studies
Multiple Myeloma
Drug Resistance
Methotrexate
Cyclophosphamide
Patient Selection
Immunity
Appointments and Schedules
Maintenance

Keywords

  • Angiogenesis
  • Bevacizumab
  • Chemo-switching
  • Cyclophosphamide
  • Immunity
  • Maintenance
  • Metronomic chemotherapy
  • Toxicity

ASJC Scopus subject areas

  • Oncology
  • Hematology
  • Geriatrics and Gerontology

Cite this

Metronomic chemotherapy from rationale to clinical studies : A dream or reality? / Gnoni, Antonio; Silvestris, Nicola; Licchetta, Antonella; Santini, Daniele; Scartozzi, Mario; Ria, Roberto; Pisconti, Salvatore; Petrelli, Fausto; Vacca, Angelo; Lorusso, Vito.

In: Critical Reviews in Oncology/Hematology, Vol. 95, No. 1, 01.07.2015, p. 46-61.

Research output: Contribution to journalArticle

Gnoni, A, Silvestris, N, Licchetta, A, Santini, D, Scartozzi, M, Ria, R, Pisconti, S, Petrelli, F, Vacca, A & Lorusso, V 2015, 'Metronomic chemotherapy from rationale to clinical studies: A dream or reality?', Critical Reviews in Oncology/Hematology, vol. 95, no. 1, pp. 46-61. https://doi.org/10.1016/j.critrevonc.2015.01.008
Gnoni, Antonio ; Silvestris, Nicola ; Licchetta, Antonella ; Santini, Daniele ; Scartozzi, Mario ; Ria, Roberto ; Pisconti, Salvatore ; Petrelli, Fausto ; Vacca, Angelo ; Lorusso, Vito. / Metronomic chemotherapy from rationale to clinical studies : A dream or reality?. In: Critical Reviews in Oncology/Hematology. 2015 ; Vol. 95, No. 1. pp. 46-61.
@article{f27fd568c52743a9a71c20bcc45ab437,
title = "Metronomic chemotherapy from rationale to clinical studies: A dream or reality?",
abstract = "Metronomic chemotherapy (MC) refers to the close administration of a chemotherapeutic drug for a long time with no extended drug-free breaks. It was developed to overcome drug resistance, partly by shifting the therapeutic target from tumor cells to the tumor vasculature, with less toxicity. Because of this peculiar way of administration, MC can be viewed as a form of long-term 'maintenance' treatment, and can be integrated with standard and conventional chemotherapy in a {"}chemo-switching{"} strategy. Additional mechanisms are involved in its antitumor activity, such as activation of immunity, induction of tumor dormancy, chemotherapy-driven dependency of cancer cells, and the '4D effect'. In this paper we report the most important studies that have analyzed these processes. In fact, a number of preclinical and clinical studies in solid tumors as well as in multiple myeloma, have been reported regarding several chemotherapy drugs which have been proposed with a metronomic schedule: vinorelbine, cyclophosphamide, capecitabine, methotrexate, bevacizumab, etoposide, gemcitabine, sorafenib, everolimus and temozolomide. The results of these studies have been sometimes conflicting, highlighting the need to develop reliable tools for patient selection and stratification. However, a more precise evaluation of MC strategies with the ongoing randomized phase II/III clinical is fundamental, because of the strict correlation of this approach with translational research and target therapy. Moreover, because of the low toxicity of MC, these studies will also help to better evaluate the clinical benefit of this treatment, with a special focus on elderly and low performance status patients.",
keywords = "Angiogenesis, Bevacizumab, Chemo-switching, Cyclophosphamide, Immunity, Maintenance, Metronomic chemotherapy, Toxicity",
author = "Antonio Gnoni and Nicola Silvestris and Antonella Licchetta and Daniele Santini and Mario Scartozzi and Roberto Ria and Salvatore Pisconti and Fausto Petrelli and Angelo Vacca and Vito Lorusso",
year = "2015",
month = "7",
day = "1",
doi = "10.1016/j.critrevonc.2015.01.008",
language = "English",
volume = "95",
pages = "46--61",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Metronomic chemotherapy from rationale to clinical studies

T2 - A dream or reality?

AU - Gnoni, Antonio

AU - Silvestris, Nicola

AU - Licchetta, Antonella

AU - Santini, Daniele

AU - Scartozzi, Mario

AU - Ria, Roberto

AU - Pisconti, Salvatore

AU - Petrelli, Fausto

AU - Vacca, Angelo

AU - Lorusso, Vito

PY - 2015/7/1

Y1 - 2015/7/1

N2 - Metronomic chemotherapy (MC) refers to the close administration of a chemotherapeutic drug for a long time with no extended drug-free breaks. It was developed to overcome drug resistance, partly by shifting the therapeutic target from tumor cells to the tumor vasculature, with less toxicity. Because of this peculiar way of administration, MC can be viewed as a form of long-term 'maintenance' treatment, and can be integrated with standard and conventional chemotherapy in a "chemo-switching" strategy. Additional mechanisms are involved in its antitumor activity, such as activation of immunity, induction of tumor dormancy, chemotherapy-driven dependency of cancer cells, and the '4D effect'. In this paper we report the most important studies that have analyzed these processes. In fact, a number of preclinical and clinical studies in solid tumors as well as in multiple myeloma, have been reported regarding several chemotherapy drugs which have been proposed with a metronomic schedule: vinorelbine, cyclophosphamide, capecitabine, methotrexate, bevacizumab, etoposide, gemcitabine, sorafenib, everolimus and temozolomide. The results of these studies have been sometimes conflicting, highlighting the need to develop reliable tools for patient selection and stratification. However, a more precise evaluation of MC strategies with the ongoing randomized phase II/III clinical is fundamental, because of the strict correlation of this approach with translational research and target therapy. Moreover, because of the low toxicity of MC, these studies will also help to better evaluate the clinical benefit of this treatment, with a special focus on elderly and low performance status patients.

AB - Metronomic chemotherapy (MC) refers to the close administration of a chemotherapeutic drug for a long time with no extended drug-free breaks. It was developed to overcome drug resistance, partly by shifting the therapeutic target from tumor cells to the tumor vasculature, with less toxicity. Because of this peculiar way of administration, MC can be viewed as a form of long-term 'maintenance' treatment, and can be integrated with standard and conventional chemotherapy in a "chemo-switching" strategy. Additional mechanisms are involved in its antitumor activity, such as activation of immunity, induction of tumor dormancy, chemotherapy-driven dependency of cancer cells, and the '4D effect'. In this paper we report the most important studies that have analyzed these processes. In fact, a number of preclinical and clinical studies in solid tumors as well as in multiple myeloma, have been reported regarding several chemotherapy drugs which have been proposed with a metronomic schedule: vinorelbine, cyclophosphamide, capecitabine, methotrexate, bevacizumab, etoposide, gemcitabine, sorafenib, everolimus and temozolomide. The results of these studies have been sometimes conflicting, highlighting the need to develop reliable tools for patient selection and stratification. However, a more precise evaluation of MC strategies with the ongoing randomized phase II/III clinical is fundamental, because of the strict correlation of this approach with translational research and target therapy. Moreover, because of the low toxicity of MC, these studies will also help to better evaluate the clinical benefit of this treatment, with a special focus on elderly and low performance status patients.

KW - Angiogenesis

KW - Bevacizumab

KW - Chemo-switching

KW - Cyclophosphamide

KW - Immunity

KW - Maintenance

KW - Metronomic chemotherapy

KW - Toxicity

UR - http://www.scopus.com/inward/record.url?scp=84930821569&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930821569&partnerID=8YFLogxK

U2 - 10.1016/j.critrevonc.2015.01.008

DO - 10.1016/j.critrevonc.2015.01.008

M3 - Article

VL - 95

SP - 46

EP - 61

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

IS - 1

ER -